Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
Cash from Investing Activities
Antisense Therapeutics Ltd
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Antisense Therapeutics Ltd
ASX:ANP
|
Cash from Investing Activities
-AU$29.3k
|
CAGR 3-Years
-42%
|
CAGR 5-Years
59%
|
CAGR 10-Years
-11%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Investing Activities
AU$473.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Investing Activities
-AU$211.5m
|
CAGR 3-Years
-3 179%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-171%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Investing Activities
-AU$16.7m
|
CAGR 3-Years
-902%
|
CAGR 5-Years
-332%
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Investing Activities
-AU$14.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Investing Activities
AU$3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Antisense Therapeutics Ltd's Cash from Investing Activities?
Cash from Investing Activities
-29.3k
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Cash from Investing Activities amounts to -29.3k AUD.
What is Antisense Therapeutics Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-11%
Over the last year, the Cash from Investing Activities growth was -649%. The average annual Cash from Investing Activities growth rates for Antisense Therapeutics Ltd have been -42% over the past three years , 59% over the past five years , and -11% over the past ten years .